Psoriasis is a hyperproliferative skin disorder in which immune mechanisms are thought to playa role. Recently, cyclospOlin A has been found effective to treat psoriasis. However, mechanisms of action of cyclosporin A in patients are not well understood. We investigated seven patients (6 males. I female, aged 29-58 years) with severe psoriasis, three of them associated with arthropathy. The patients were treated with cycJopsorin A given twice daily in gelatine capsules. Four patients were given 5 mg/kg, the others received 2.5 mg/kg initially. Two of them were put on 5 mg/kg (after 4 and 12 weeks of treatment). Clinical (,valuation before and during therapy was canied out using the Psoriasis Area and Severity Index (PAS[). Patients were followed up for 6 and 15 months. Their cycJosporin A blood levels were adjusted by a monoclonal radioimmunoassay. In parallel, serum and urine neopterin levels were quantified by HPLC. Mean neopterin concentrations in patients prior to therapy were found only slightly higher (serum 6.5± 0.8 mmolll) than in healthy controls. There was no correlation of neopterin values and the degree of PASIscore. Onset of cyclospOlin A was paralleled by decreasing neopterin concentrations and improvement of the skin status. Decrease of cyclospOlin A doses was accompanied by an increase of PAS1 and significantly decreasing neopterin levels. In patients with severe relapses of psoriasis after withdrawal of cyclosporin A, neopterin rose higher than pretreatment levels. [n 6/7 patients PASI and neopterin levels were closely correlated.
Introduction
Psoriasis is a common chronic, inflammatory skin disorder. There is evidence for an important role of immune mechanism in the pathogenesis of psoriasis (1). The recent introduction of cyclosporin A, which inhibits T-cell activation and cytokine release. as a highly effective treatment of psoriasis (2) had also an impact for the understanding of the immunological mechanisms of psoriasis.
Interferon-gamma (IFN-gamma) is detectable in pSOliatic epidennis (3) , and the intradermal administration of IFN-gamma to human individuals somePteridines \ 0 1. 4
:\ 0 . . ~ times provokes clinical and histopathological changes comparable to psoriasis (4) . Since neopterin is released by macrophages upon stimulation by IFN-gamma (5), we were interested whether the clinical response of psoriasis to cyclosporin A is accompanied by changes in the serum or urine neoptcrin levels.
Methods
We investigated seven patients (6 males, I female, aged 29-58 years) with severe psoriasis (Psoriasis Activity and Severity Index-PASI-score-:~~20), three of them associated with arthropathy. The patients were treated with eyclosporin A (Sandoz. Baste. Switzerland) given twice daily in gelatine capsules. Four patients were given 5 mg/kg hod y weight. th e o thers received 2.5 mg/kg. initia ll y. Two of the latter patients were put on 5 m gJkg late r on (after 4 and 12 weeks of treatment) heca use of an unsati s t~lc tory respon se on the lower dosage of cyclosporin A Clinical evaluatio n hefo re. during a nd after thera py was eanied out using the PAS I sco re. Pa tients were followed up for 10 to 18 month s. Determin ation of serum and urinary neopterin levels was performed. Serum n eopterin concentrations were evaluated usi ng radi o immunoassay (H enning-Berlin. Germany) (6) . Neopterin in urine sampl es was assessed using high perfo rma nce liquid chromatograph y (HPLC ) as previously deselihed (7) . Neopterin concentrations were rel~lted to co ncomitantly determin ed creatinine levels to compensate. for physio logical va riatio ns of Ulin e diluti o n.
Statistics
For comparison of paired data. Wilcoxon paired rank test was app li ed. Correlation analyses we re perform ed u sing Spea rman rank correlation test.
Results
Clinically all patie nts responded well after 6 weeks with the S mg/kg dosage. Pretreatment mean PASI-index of 24± 2.3 wa s reduced hy 5 m g/kg cyclosporin A to mea n va lues of S±3.9 (p<O.OI) after 6 weeks of treatme nt. Five patients tolerated therapy well. Side effects in two patients (herpes zoster. nephrotoxicity) led to disco ntinu a tion of thera py.
Mea n neo tperin conce ntratio ns in patients pri o r
[0 therapy werc found to he o nly slightly higher (mean ± S.D.: 6.5± 0.8 ninol/I) th a n in health y controls (S.3± 2.7; not sig nifica nt). Only one out of these patients had se rum a nd neopterin levels hefore treatment with cyclospo rin A ahove 8.7 nmol/1. which is th e 9th percentil e of health y controls (6) . There was no correlation of neopterin values and the degree of PASI-score (Tahle 1).
Onset of cyc1osporin A with the higher dosage of 5 mgJkg hody weight was paralleled hy decreasing neopterin concentrations and improvement of the skin status. D ecrease of cyclosporin A dosage was acco mpa nied by an increase of P AS I and neopterin (Fig. I) . Compared to pretreatment levels significantly decreased neopterin levels either in serum o r in urine were o hserved during therapy (p<0.05).
Pteridines ! Vol. 4 *Neoptcrin increased com pa red 10 average of no rm a l hea lth y con tro ls of sa me age (senlill in nIl1ol/1. urine in jJlllol/ mol creati nine) 28 14 240 . 1 A correlation hetween urin e and serum neopte rin levcls was ohserved during therapy (rs=0.786. p = O.OS). Seru m a nd urine concentrations correlated mode rately with PASI-score before therapy was stopped (rs = 0.600. p = O.14 and rs = 0.709. p = 0.08). In two young patie nts. who suffered from severe rela pses o f psoriasi s a fter withdrawal of cyclosporin A serum and urine neoptcrin concentrations rose hig he r th a n pretreatme nt levels. In 6 or 7 patients P AS I and neopterin levels during follow-up were closely con·elated. in o ne patient less so (p = OJ) 18). Two typical co urses of PASI-scores a nd neopterinlevels during fo llow-up are shown in Figs. 2 a nd 3: In patient 3 increase of se rum neopte rin levels preceded the relapse o f psoriasis (Fig. 2) , whereas in patient 6 increase a nd dec rease in serum neopterin levels correlated time-dependently with increase and decrease of PAS I (Fig. 3) . The increase of PASIscore and serum neopterin-levcls a fter withdrawal of therapy was significant (Fig. I) ; it was less so 
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Weeks from start of therapy for urinary neopterin levels (z= 1.16, p =O. II). In contrast to neopterin levels PASI-score sti ll stayed lower than pretreatment levels (z=2.1D. p=OJl4).
Discussion
Our results correspond to previous investigations which demonstrated IFN-ga mma in the epidermis of psoriasis patients (3). Increase and decrease of neo pterin concentrations in patients with psoriasis depend on th e clinical status of the disease in individual patients but no association between neoptcrin levels and PASI was observed cross-sectionally. The data suggest an involvement of endogenously released IFN-gamma. which induces release of neopterin by human monocytes and macrophages in the path oge nesis of pSOliasis. H oweve r, the pretreatment 151 value of serum neopterin was elevated in only one patient. This may be explained by the fact that on the one hand. the neopterin molecule does not sufficie ntly diffuse from the periphery into the blood stream (9) a nd on th e other hand, th e release of IFN-gamma is more important for the neighbouring keratinocytes in loco.
The involvement of IFN-gamma in the pathogenesis of psoriasis would explain some of the clinical phenomena. Under normal conditions, IFN-Ievels in peripheral blood are not detectable in psoriasis patients (unpublished data). Also, neopterin levels a re within the normal range in th e majority of patients.
Infections with viruses, for example. with a massive production of IFN-gamma and neopterin are often accompanied by the occurrence or relapse of pso riasis. During virus infections highly increased neopterin-lcvels are observed (10) which indicate Tce1\ activation and production of IFN-gamma. In our study. a rebound phenomenon with a massive relapse of psoriasis was accompanied by dramatically increasi ng neoptelin levels (Figs. 2. 3) . Likewise a melioration of psoriasis is often observed after viral infections. Interestingly an increase of urinary neoprerin levels was also descri bed earlier in kidney allogra ft recipi ents after withdrawal of cyclosporin th e rapy (8). These data may indicate that cytokine pathways, like IFN-gamma release. which are inhibited by cyclosporin A became reactivated after withdrawal of th erapy.
I n contrast to recent results of Harla nd el (1/ (1 I), there was no significant correlation of PASI-index a nd urine neopterin levels in our study. However. the number of patients is certainly too small for a final conclusion. In add ition to that, our study revealed genera1\y nonna l neopterin levels of patients with severe chronic plaque p"uriasis compared to healthy controls; howeve r, during follow-up, increase and dec rease of PAST was associated with incrcase and decrease of neopterin concentrations in a ll patients. Our findings a nd also the results of other studies (3. 4) may indicate that IFN-gamma plays an impol1ant pathogenetic role in the development of pSOIiatic lesions. This may also explain th e clinical phenomenon of virus infection associated relapse of psoriasis as well as of th e psoriasis associated with human immunodeficiency infection (12): In these patients significantly elevated serum IFNgamma levels were found as well as eleva ted serum neopterin levels (10. 13). In psoriasis. probably activa tion of T-ce1\s is foll owed by a release of IFN-gamma, which acts as a proinflammatory cytokine in skin a nd may also be importa nt in the epi-dennotropism of T-lymphocytes in psoriasis (14) . Our data are in line with observations of others (I. 3. 4) suggesting an important role of IFN-gamma in the pathogenesis of psoriasis.
